Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Maria Grazia Roncarolo, MD
Healthcare Provider Professor of Pediatrics
Lorry I. Lokey Stem Cell Research Building
265 Campus Drive West
Room G3021A
Stanford, California, United States
Maria Grazia Roncarolo, MD is the co-director of the Institute for Stem Cell Biology and Regenerative Medicine, the George D. Smith Professor in Stem Cell and Regenerative Medicine, Professor of Pediatrics and of Medicine (blood and marrow transplantation), chief of the Division of Pediatric Stem Cell Transplantation and Regenerative Medicine, and co-director of the Bass Center for Childhood Cancer and Blood Diseases.
Dr. Roncarolo developed new gene-therapy approaches, which she pursued as director of the Telethon Institute for Cell and Gene Therapy at the San Raffaele Scientific Institute in Milan. She was the principal investigator leading the successful gene therapy trial for SCID patients who lack an enzyme critical to DNA synthesis, which is a severe life-threatening disorder. That trial is now considered the gold standard for gene therapy in inherited immune diseases. Under her direction, the San Raffaele Scientific Institute has been seminal in showing the efficacy of gene therapy for otherwise untreatable inherited metabolic diseases and primary immunodeficiencies. Her goal at Stanford is to build the teams and infrastructure to move stem cell and gene therapy to the clinic quickly and to translate basic science discoveries into patient treatments.
+myBinderRelated Content
-
Howard Woolley, MASHoward Woolley is a philanthropist with ...
-
Sickle Cell Center of Southern LouisianaThe Tulane University Sickle Cell Center...
-
Nadine Matthie, PhD, RNNadine Matthie is an assistant professor...
-
Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-bas...The clinical efficacy of hydroxyurea in ...
-
GlycoMimetics Announces Pricing of Public Offering of Common StockGlycoMimetics, Inc. (NASDAQ: GLYC), a cl...
-
Your Healthcare TeamTo seek clinical care for your sickle ce...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
